Atagabalin (, ; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.
Atagabalin (, ; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.
==See also== List of investigational insomnia drugs 4-Methylpregabalin Gabapentin enacarbil PD-217,014 PD-0299685
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).